TORREY PINES, Calif., Jan. 20, 2023 /PRNewswire/ -- EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of RRx-001 vs. regorafenib in patients with third/fourth line colorectal cancer has been selected for a poster presentation at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium being held January 19-21 in San Francisco. The Phase 2 study, called ROCKET, compares the safety and efficacy of RRx-001 plus irinotecan vs. regorafenib in 34 patients with third/fourth line colorectal cancer that were previously treated with irinotecan-based therapy.
LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that regorafenib has completed enrollment and follow-up in GBM AGILE. Enrollment for the arm was stopped after an interim analysis showed a low probability of sufficient improvement in overall survival as compared with randomized controls.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Commission (EC) has approved QINLOCK® (ripretinib) in the European Union (EU) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib1. The EC decision is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. In September 2021, QINLOCK was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST2.
VIRTUAL -- June 7, 2021 -- Pimitespib, a highly potent oral heat shock protein 90 (HSP90) inhibitor, shows significant benefit in survival outcomes in the treatment patients with advanced gastrointestinal stromal tumour (GIST) who are resistant to standard therapies, according to a study presented at the Virtual 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Updated efficacy and safety data for Vitrakvi® (larotrectinib) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients New safety and efficacy data from established compounds including Xofigo® (radium Ra 223 dichloride) and Stivarga® (regorafenib)
OnQuality Pharmaceuticals has raised $15 million in first-round financing to fund development of a drug that treats side effects of VEGF inhibitors for cancer.
Bristol-Myers Squibb’s Opdivo couldn’t quite beat Nexavar, the standard of care in hepatocellular carcinoma, in its Phase III head-to-head. But investigators are still hoping that it can play a role in the frontline setting of this disease.
One class of proteins was at the heart of nearly $100 billion worth oncology M&A over the past decade, according to a new report.
Deciphera Pharmaceuticals' ripretinib kept patients with advanced gastrointestinal stromal tumors (GIST) from progressing significantly longer than those on placebo, outperforming analyst expectations